13F Holdings
中文EN

CRVS Corvus Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1626971 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-326.6%
TTM EPS YoY-33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-45.9%
ROA-42.3%
ROIC (approx.)-40.8%
Asset turnover—

Leverage & solvency

Liabilities / assets6.9%
Debt / equity0.00x
Current ratio13.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20212022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$33.72M$19.39M$16.53M$24.47M$29.11M
SG&A expense$9.25M$8.16M$6.88M$8.10M$9.52M
Operating income-$42.97M-$27.55M-$23.41M-$32.56M-$38.63M
Pretax income-$13.32M-$59.10M-$21.75M-$31.30M-$43.24M
Income tax$0$0$0$0$0
Net income-$15.28M-$62.29M-$27.03M-$41.31M-$43.24M
EBITDA-$42.87M-$27.46M-$23.26M-$32.20M-$38.17M
EPS (basic)-0.19-1.02-0.56-0.89-1.03
EPS (diluted)-0.53-1.02-0.56-0.89-1.03
Weighted avg. shares (diluted)79.74M60.99M48.03M46.55M41.85M
Balance sheet
Cash & equivalents$4.58M$8.74M$12.62M$13.16M$63.46M
Short-term investments$52.17M$43.22M———
Receivables$37,000$75,000$26,000$588,000—
Current assets$58.21M$54.41M$27.96M$43.66M$71.31M
PP&E, net$220,000$151,000$236,000$353,000$451,000
Total assets$71.12M$68.91M$45.55M$68.24M$109.45M
Current liabilities$9.38M$35.40M$6.87M$10.75M$9.69M
Total liabilities$9.91M$36.34M$6.87M$12.12M$12.29M
Shareholders' equity$61.20M$32.57M$38.68M$56.12M$97.16M
Shares outstanding74.70M67.90M49.04M46.55M46.55M
Cash flow statement
Operating cash flow-$32.80M-$25.42M-$23.93M-$27.02M-$36.72M
Capital expenditure$174,000—$34,000$269,000$5,000
Free cash flow-$32.97M—-$23.97M-$27.29M-$36.72M
Investing cash flow-$7.80M-$27.48M$15.54M-$23.28M$21.56M
Financing cash flow$36.43M$49.03M$7.86M$0$62.16M
Depreciation & amortization$105,000$85,000$151,000$367,000$460,000
Stock-based compensation$5.33M$3.00M$2.15M$2.69M$4.23M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.